Information on vaccines available (at the time of review, November 2020) in the UK and relevant to the HBLB Codes of Practice
|Equip Artervac*||Zoetis||For the active immunisation of horses and ponies against equine arteritis virus (EAV) in order to reduce clinical signs and shedding of virus in bodily secretions after infection.|
|Equip EHV-1,4||Zoetis||For active immunisation of horses to reduce clinical respiratory signs due to infection with EHV-1 and EHV-4 and to reduce abortion caused by EHV-1 infection.|
|Equip F||Zoetis||For active immunisation of horses against EI, to reduce clinical signs and shedding of virus after infection.|
|Equilis Prequenza||MSD Animal Health||For active immunisation of horses against EI, to reduce clinical signs and shedding of virus after infection.|
|Proteq Flu||Boehringer Ingelheim||For active immunisation of horses against EI, to reduce clinical signs and shedding of virus after infection|
|Equip WNV||Zoetis||For the active immunisation of horses of 6 months of age or older against WNV disease by reducing the number of viraemic horses after infection with WNV lineage 1 or 2 strains and to reduce duration and severity of clinical signs against WNV of lineage 2 strains|
|Proteq West Nile||Boehringer Ingelheim||For active immunisation of horses from 5 months of age against WNV disease by reducing the number of viraemic horses. If clinical signs are present, their duration and severity are reduced.|
Veterinary advice should be sought on the choice, timing and administration of any vaccine.
*Veterinary surgeons and horse owners should be aware that the current datasheet requirement for the only inactivated EAV vaccine currently licensed for use in Europe (Equip Artervac) is for six monthly boosters and not 12 monthly (annual) boosters as was originally the case for this vaccine. This has been the requirement since April 2005, when the vaccine was granted a full market authorisation by the Veterinary Medicines Directorate (VMD) in the UK. Noncompliance with this booster interval requirement may necessitate investigation of the viral shedding status of stallions by Defra/APHA under the Equine Viral Arteritis Order 1995.
Vaccination is recommended as one means of aiding the prevention of disease. The listing of vaccines above is for information purposes only and does not imply endorsement of the products by the HBLB, its Veterinary Advisory Committee or Sub-Committees. The information given is accurate at the time of printing.